trial

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

NCTId NCT03034356
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 67 (actual)
Sponsored by VA Office of Research and Development
Primary completion 2024-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
67 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2018-09-01
Primary completion
2024-06-30
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Levetiracetam

Sponsors

VA Office of Research and DevelopmentLead Sponsor

Investigators

1
Jason R. Tregellas, PhDPrincipal Investigator

Sites

1 total
Aurora, United States

Linked catalysts

1
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia — primary completion2024-06-30

Facts & assertions

4 sourced
Enrollment
67
Phase
PHASE1,PHASE2
Primary Completion Date
2024-06-30
Status
COMPLETED
relationships
The graph out of here
drug
Levetiracetam
drug
lead_sponsor
VA Office of Research and Development
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jason R. Tregellas, PhD
person